Bryan Johnson's Partner Microbiome Tracking Raises Questions About Health Monitoring and Privacy

Tech entrepreneur Bryan Johnson, known for spending millions annually on extreme anti-aging treatments, has begun regularly testing his girlfriend's vaginal microbiome using commercial at-home testing kits. The practice reflects the growing market for these tests, with companies like Evvy, Tiny Health, Viome, and ZOE offering services ranging from $199 to $600 per test. Johnson's adoption of this approach brings the so-called "quantified-self" movement—tracking and optimizing personal health metrics—into new territory.

The Market for Vaginal Microbiome Testing

At-home vaginal microbiome tests have matured into a legitimate consumer health category. Evvy positions itself as the first consumer mNGS test for vaginal health, where mNGS stands for a DNA sequencing method that identifies multiple microbial species at once. The company holds CLIA and CAP certifications, which verify laboratory quality standards. Other competitors take different technical approaches and price points.

Tiny Health uses a sequencing technique called shotgun metagenomics—think of it as identifying all the DNA fragments in a sample to map which bacteria and fungi are present—and charges $249 to $600. Viome offers RNA sequencing, which captures which microbes are actively functioning, at $199-$399. ZOE uses deep shotgun metagenomics at around $299.

The technical differences matter. Most consumer microbiome tests use targeted DNA sequencing that focuses on a narrow set of bacteria. The more advanced platforms using shotgun approaches can identify a wider range of organisms and sometimes show which ones are actually active in the body.

What the Research Says

The expansion of these tests follows genuine clinical research. Studies have found that the mix of bacteria in the vaginal microbiome correlates with pregnancy outcomes. Research published in Nature Medicine has linked vaginal microbiome diversity to preterm birth risk. Other studies have mapped which bacterial patterns, particularly those involving Lactobacillus species, are associated with earlier deliveries and explored how the microbiome interacts with cervical length and progesterone treatment.

To make these findings actionable in consumer tests, researchers had to develop better ways to store samples and improve the reference databases used to identify bacteria accurately. However, the research establishes a connection between microbial composition and certain reproductive health outcomes.

The Broader Context

Johnson's approach represents an extreme extension of health monitoring that gained broader attention after Bloomberg featured his anti-aging regimen in January 2023, which includes tracking dozens of personal health metrics and spending heavily on interventions.

Here's where the story becomes complicated. Vaginal microbiomes are not static the way genetic information is. They shift with menstrual cycles, sexual activity, antibiotic use, and other factors. Testing one's partner's microbiome means creating an ongoing stream of biological data from someone else's body—not a single snapshot. That raises questions about data ownership, consent, and what exactly constitutes health optimization versus surveillance within an intimate relationship. We have seen similar privacy tensions before, when early adopters of consumer genetic testing shared family members' results before the implications of doing so became clearer.

What We Don't Know Yet

The scientific question of whether frequent vaginal microbiome testing actually improves health in people without reproductive complications remains open. Yes, research shows that microbiome composition matters for certain pregnancy outcomes. But the next step—what to do if testing reveals a "suboptimal" microbiome in a healthy person—is not yet settled in clinical practice.

Lactobacillus-dominated bacterial communities are generally considered healthy. But beyond that general principle, the best interventions for changing microbiome profiles are still under investigation. Consumer testing platforms also differ in their ability to detect clinically relevant organisms and generate truly actionable insights. CLIA certification ensures the lab itself works to a high standard, but different companies use different algorithms to interpret what the data means.

As these testing technologies become cheaper and more detailed, Johnson's case may preview a broader conversation about the appropriate boundaries of health optimization—both about what we monitor in ourselves and what we monitor in others. The technology is outpacing our social and ethical consensus about what to do with it.